Managed Healthcare Executive August 5, 2024
Driving this growth will be the approvals of novel biologics, such as gene therapy, RNA-based therapeutics, and antibody-drug conjugates.
The global biologics market is expected to reach $1.37 trillion by 2033, growing more than 10% from 2023, according to a recent report by Nova One Advisor. Contributing to this growth will be the approvals of novel biologics, such as gene therapy, RNA-based therapeutics, and antibody-drug conjugates.
Monoclonal antibodies account for the largest number of biologics currently approved by regulatory authorities, and oncology had the largest share (29.4%) of approved biologics in 2023. From now to 2033, the hematological disorder segment is expected to expand at the fastest compound annual growth rate of 11.8%. Researchers said the approvals of gene therapies...
Today's Sponsors
Today's Sponsor